Johnson & Johnson Recalls Schizophrenia Drug for Mold

Johnson & Johnson Recalls 5,000 vials of Risperdal Consta

   

Johnson & Johnson Recalls Schizophrenia Drug for Mold

jnj logo Johnson & Johnson Recalls Schizophrenia Drug for MoldJohnson & Johnson (JNJ) is recalling 5,000 vials of its schizophrenia drug, Risperdal Consta, due to concerns of mold.

One batch of the drug was found to contain alternaria alternata, a mold commonly found in the area. There have yet to be any negative reports regarding the medicine, but Johnson & Johnson says that injection site reactions could happen. The 5,000 vials being recalled are what’s left of the 70,000 vials that were originally manufactured. The vials are mostly located with wholesalers, distributors, pharmacies and doctor’s offices. Johnson & Johnson claims that the risk to patients is low and that the recall won’t affect its Risperdal medication that is taken orally, reports Bloomberg.

“The quality of our products is a primary concern of ours, and all of our products undergo rigorous testing,” a Johnson & Johnson spokeswoman told The Wall Street Journal.


Article printed from InvestorPlace Media, http://investorplace.com/2013/09/johnson-johnson-recalls-schizophrenia-drug-for-mold/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.